p27(Kip1 )is expressed in proliferating cells in its form phosphorylated on threonine 187 by Troncone, Giancarlo et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Clinical Pathology
Open Access Research article
p27Kip1 is expressed in proliferating cells in its form phosphorylated 
on threonine 187
Giancarlo Troncone*1, Juan C Martinez2, Antonino Iaccarino1, Pio Zeppa1, 
Alessia Caleo1, Maria Russo1, Ilenia Migliaccio1, Maria L Motti3, 
Daniela Califano4, Emiliano A Palmieri1 and Lucio Palombini1
Address: 1Dipartimento di Scienze Biomorfologiche e Funzionali, Facoltà di Medicina e Chirurgia, Università Federico II, Napoli, Italy, 2Istituto 
Oftalmico, Hospital Universitario Gregorio Maranon, Madrid, Spain, 3Dipartimento di Biologia e Patologia Cellulare e Molecolare "L Califano", 
Facoltà di Medicina e Chirurgia, Università Federico II, Napoli, Italy and 4Dipartimento di Oncologia Sperimentale, Fondazione G. Pascale, 
Napoli, Italy
Email: Giancarlo Troncone* - giancarlo.troncone@unina.it; Juan C Martinez - jcmartinezmont@jazzfree.com; 
Antonino Iaccarino - antiacc@aliceposta.it; Pio Zeppa - zeppa@unina.it; Alessia Caleo - alessiacaleo@hotmail.com; 
Maria Russo - mimmarusso@tiscali.it; Ilenia Migliaccio - ileniamig@gsmbox.it; Maria L Motti - rmotti@libero.it; 
Daniela Califano - dcalifano@yahoo.com; Emiliano A Palmieri - eapalmieri@ciaoweb.it; Lucio Palombini - palombin@unina.it
* Corresponding author    
Abstract
Background: G1/S cell cycle progression requires p27Kip1 (p27) proteolysis, which is triggered by
its phosphorylation on threonine (Thr) 187. Since its levels are abundant in quiescent and scarce in
cycling cells, p27 is an approved marker for quiescent cells, extensively used in histopathology and
cancer research.
Methods: However here we showed that by using a specific phosphorylation site (pThr187)
antibody, p27 is detectable also in proliferative compartments of normal, dysplastic and neoplastic
tissues.
Results:  In fact, whereas un-phosphorylated p27 and MIB-1 showed a significant inverse
correlation (Spearman R = -0.55; p < 0,001), pThr187-p27 was positively and significantly
correlated with MIB-1 expression (Spearman R = 0.88; p < 0,001). Thus proliferating cells only stain
for pThr187-p27, whereas they are un-reactive with the regular p27 antibodies. However
increasing the sensitivity of the immunocytochemistry (ICH) by the use of an ultra sensitive
detection system based on tiramide signal amplification, simultaneous expression and colocalisation
of both forms of p27 was shown in proliferating compartments nuclei by double
immunofluorescence and laser scanning confocal microscopy studies.
Conclusion: Overall, our data suggest that p27 expression also occurs in proliferating cells
compartments and the combined use of both regular and phospho- p27 antibodies is suggested.
Background
Immunocytochemistry (ICH) is an important method for
identification of proteins in cells and in tissues. Since the
biological activity of many proteins is dependent on their
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phosphorylation status, a challenge for immunocyto-
chemistry is to characterize the protein form and not just
the total amount [1]. p27Kip1 (p27) is a key inhibitor of
cell division that protects tissues from excessive cell prolif-
eration [2]. As a consequence of an altered balance
between synthesis and degradation, the amounts of this
protein are abnormally low in advanced and poorly differ-
entiated neoplasms [3]. Since p27 expression is readily
assessed by ICH, this protein is a prognostic marker quite
popular in histopathology [4]. However, little is known
on its in vivo regulation. p27 cellular levels, copious in
quiescent cells undergoing terminal differentiation, are
scanty in cycling cells [2]; in these cells p27 is phosphor-
ylated on Thr 187 by cyclin-dependent kinase (cdk) 2 in
late G1 [5]. This event leads to enhanced ubiquitination
and p27 proteolysis by the proteasome, which marks the
restriction point and promotes cell proliferation [5].
Therefore un-phosphorylated ("plain") p27 is representa-
tive of the total protein amounts only in quiescent cells,
whereas in cycling cells a fraction of p27 is transiently
present in the pThr187 form before degradation [5].
Recently, Montagnoli et al raised an antibody (Ab), spe-
cific for pThr187-p27 that was reactive in immunoprecip-
itates from proliferating cells and negative in quiescent
cells [6]. Even more recently this Ab was shown to be reac-
tive also on paraffin sections [7,8]. The present study was
undertaken to assess pThr187-p27 Ab staining pattern in
a wide range of normal, dysplastic and neoplastic tissues;
its expression was correlated to those of MIB-1, a standard
marker of proliferation, and of "plain" p27. The relation-
ship between the two forms of p27 was also studied at a
sub cellular level by double immunofluorescence (IF) and
laser scanning confocal microscopy (LSCM). Here we
show that p27 expression is not restricted to quiescent
cells but that it also occurs in proliferating cellular com-
partments, where it is detectable by regular ICH only in its
pThr187 form. Therefore, to fully assess p27 tissue expres-
sion both antibodies should be used.
Methods
Antibodies
pThr187-p27 was detected by the 71–7100 polyclonal
antibody (PcAb) (Zymed Laboratories, San Francisco, CA,
USA) and by the sc-16324 PcAb (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA, USA). These Ab's were raised
against a short peptide corresponding to the portion of
human p27 containing phosphorylated Thr-187, in order
to detect only phospho-p27 and to be unreactive with
"plain"-p27. The 71–7100 Ab was previously employed in
immuno-precipitation experiments by Western blot,
[6,9,10] and to immunostain neoplastic and degenerative
human tissue [7,8].
"Plain" p27 protein levels were detected with the K10125
monoclonal Ab (McAb) from (Transduction Laboratories,
Lexington, Ky, USA), and with the rabbit PcAb (C-19)
(Santa Cruz Biotechnology). These antibodies were previ-
ously shown to share the same staining pattern [11]. MIB-
1 McAb from Novocastra (Newcastle upon Tyne, UK) was
used to stain proliferating cells and as control of antigenic
preservation and of successful antigenic retrieval [12].
Tissues
A wide range of normal, dysplastic and neoplastic tissues
was obtained from surgical specimens. At least five sam-
ples from each type of normal tissue were processed
(Table 1). Dysplastic diseases included five cases of
colonic adenoma, five cases of low- and five cases of high
grade- squamous intraepithelial lesions (SIL) of the uter-
ine cervix. Several carcinomas were also evaluated, includ-
ing different tumour types in which p27 down regulation
had previously been described, such as invasive squamous
cell carcinoma (ISCC) of the oral cavity (n = 7) [13], of the
lung (n = 10) [14] and of the uterine cervix (n = 9) [15];
ductal cell carcinoma of the breast (n = 12) [16]; invasive
adenocarcinoma of the colon (n = 6) [17] and of the pros-
tate (n = 5) [18]; papillary (n = 6) and anaplastic (n = 5)
thyroid carcinoma, [19], glioblastomas (n = 5) [20], and
choriocarcinoma (n = 2) [21].
Immunostaining techniques
Xylene dewaxed and alcohol rehydrated paraffin sections
were placed in Coplin jars filled with a 0.01 M tri-sodium
citrate solution, and heated for 3 minutes in a conven-
tional pressure cooker [15]. After heating, slides were
thoroughly rinsed in cool running water for 5 minutes.
They were then washed in Tris-Buffered Saline (TBS) ph
7.4 before incubating overnight with the specific Ab,
diluted as follows: anti-pThr187-p27 (Zymeed) 1:1000;
anti-pThr187-p27 (Santa Cruz) 1:200; anti-p27 (Trans-
duction) 1:4000; anti-p27 (Santa Cruz) 1:50; anti-Ki-67
1:50. After incubation with the primary Ab, tissue sections
were covered with biotinylated anti-mouse or anti-rabbit
immunoglobulins, followed by peroxidase labelled
streptavidine (LSAB-DAKO); the signal was developed by
using diaminobencidine (DAB) chromogen as substrate.
Immunostaining controls
pThr187-p27 antibody specificity was controlled by West-
ern blot analysis of MDA MB 468 (breast cancer) and NPA
(thyroid papillary cancer) cell lines. These were lysed (50
mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 0.1% Triton
X-100, 5 mmol/L ethylenediaminetetraacetic acid, 1
mmol/L Na3VO4, and 1 mmol/L phenyl methyl sulfonyl
fluoride and protease inhibitors) and 20 to 30 µg of pro-
teins were electrophoresed in sodium dodecyl sulfate-
polyacrylamide gel electrophoresis gel and transferred
onto nitrocellulose membranes. The membranes wereBMC Clinical Pathology 2005, 5:3 http://www.biomedcentral.com/1472-6890/5/3
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first blocked and then incubated with the primary anti-
body as it follows: anti-pThr187-p27 (Zymeed), 1:2000
and anti "plain" p27 (Transduction), 1:3000 for 1 hour at
room temperature. To confirm equal loading, membranes
were immunoblotted with monoclonal anti b-tubulin
antibody (1:1000, Santa Cruz). After three washes, filters
were incubated with horseradish peroxidase-conjugated
goat anti-mouse or anti-rabbit antibodies (1:2000; Amer-
sham, Arlington Heights, IL, USA) for 1 hour at room tem-
perature. Detection of immunocomplexes was performed
with an enhanced chemiluminescence system (ECL,
Amersham).
pThr187-p27 immunostaining specificity was assessed by
several control experiments performed in parallel, in
which the primary Ab was either replaced by a similarly
diluted normal rabbit serum, or adsorbed with increasing
concentrations of its phospho and dephosphopeptides
(up to 0.14 mg mL-1).
Quantitative study and statistical analysis
In the neoplastic cases examined, labelling indices for
pThr187-p27, "plain" p27 and Ki67/MIB-1 were deter-
mined. Adjacent sections were used and counting was per-
formed in similar areas; quantitative analysis performed
with a computerised analyser system (Ibas 2000, Kontron,
Zeiss) was used to score the nuclei of individual cells for
expression of these proteins. As already described, nuclear
boundary optical density and Ab threshold were adjusted
for each case examined [15]. A minimal threshold was
established by counting at least 1000 cells per sample and
the results were expressed as a percentage of the total cell
population. Statistical analysis was performed by means
of SPSS Inc. package. The range of expression of pThr187-
p27, "plain" p27 and Ki67/MIB-1 for each neoplastic type
is reported in table 2. The relationships among these were
analyzed by calculating the nonparametric Spearman R
coefficient.
Double Immunofluorscence (IF) staining and Laser 
Scanning Confocal Microscopy (LSCM)
Tissue sections from both normal and neoplastic speci-
mens were also stained using double IF labelling for
pThr187-p27 and "plain" p27, according to previous
studies with minor modifications [22]. The primary anti
pThr187-p27 (Zymeed) was incubated (1/1000) for 1
hour, followed by incubation with swine anti rabbit HRP
(1/200) (Dako) and Cy3 tyramide amplification (Perkin
Elmer Life Sciences). To avoid cross-reactivity due to resid-
ual HRP, sections were incubated with 0.3% H2O2 for 1
hour. The primary mouse McAb anti p27 (1/4000) was
detected by overnight incubation at 4°C, followed by goat
anti mouse HRP (1/200, DAKO). After washing in TBS,
sections were incubated with fluorescein isotiocyanate
Table 1: pThr187-p27, "plain"-p27 and MIB-1 expression in normal tissues.
Tissue type Phospho-p27 "plain"-p27 MIB-1
Normal squamous epithelium skin, tonsil, larynx, cervix.
Parabasal layer +++ - ++++
intermediate - ++++ +
Granular layer -+ + + -
Germinal centers Tonsil, lymphnode, apendix
Mantle cells - ++++ -
Centroblasts +++ - ++++
Centrocytes -+ + + -
Bowel Crypt cells
Deep +++ - ++++
superficial - ++++ -
Placenta
trophoblast +++ - ++++
syncytiotrofoblast - ++++ -
Kidney +/- +++ +/-
Lung +/- +++ +/-
Thyroid +/- +++ +/-
Prostate +/- +++ +/-
Key: ++++ >80% of positive cells.
+++ 50–80% of positive cells
++ 10–50% of positive cells
+ <10% of positive cells
+/- Only occasional staining
- Negative stainingBMC Clinical Pathology 2005, 5:3 http://www.biomedcentral.com/1472-6890/5/3
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(FITC) tyramide amplification (Perkin Elmer Life Sci-
ences) and mounted with Vectashield-DAPI mounting
medium (Vector). Control sections in which the second
primary Ab was omitted were included to ascertain
destruction of peroxidase activity. Single IF stained sec-
tions as well as colorimetric immunostaining were used as
controls of signal specificity. Slides were examined with a
Leica TCS SP2 UltraSpectral LaserScan Confocal micro-
scope. FITC was excited at 488 and detected with a band-
pass 500 to 550 nm. Cy3 was excited at 514 nm and
detected with a bandpass 580 to 655 nm. Series of images
were processed with the Leica confocal soft package. Con-
focal images were captured and imported into Adobe
Photoshop 7 (Adobe Systems, Mountain View, CA) and
processed with an eMac personal computer.
Results
pThr187-p27 expression in normal tissues
Similar results were obtained with both anti pThr187-p27
Ab's, with only proliferating tissue compartments being
stained. This pattern overlapped to that of Ki67/MIB-1,
whereas it was different to that shown by both Mc and Pc
Ab's directed to "plain" p27 (Table 1). Stratified squa-
mous epithelium showed the same staining pattern in
skin, tonsil, larynx and uterine cervix. In analogy to the
Ki67/MIB-1 staining, pThr187-p27 was expressed by para-
basal cells (Figure 1A); on the contrary, nuclei of the more
superficial layers showed intense "plain" p27 nuclear
labelling, as already described [13,15]. In small intestine
and colon (Figure 1B), in analogy to MIB-1, pThr187-p27
showed positivity in nuclei of deep crypt cells. On the
contrary, the upper half of the crypts was stained by
"plain" p27 [17]. In germinal centres of normal lymph
nodes, tonsil and appendix the expression of the phos-
phorylated form of p27 was clearly detectable (Figures 1A
and 1C). Within the germinal centres, pThr187-p27
showed a signal distribution similar to that of the Ki-67
protein; the outer rim of centroblast and mitotic cells were
strongly positive, whereas centrocytes were less frequently
labelled. This pattern of expression was opposite to the
one identified for "plain" p27: negative staining for cen-
troblasts and strong staining in most centrocytes, mantle
cells and interfollicular small lymphocytes [11]. Trophob-
lastic villi of placenta showed pThr187-p27 intense stain-
ing only in the cytotrophoblastic layer and not in the
syncytiotrophoblastic layer (Figure 1D). On the contrary
"plain" p27 showed intense staining only in the syncytio-
trophoblast overlying the villus, as already described [21].
In other normal tissues, comprising breast, lung, kidney,
pancreas, prostate, thyroid and parathyroid, "plain" p27
was expressed by the vast majority of cells, whereas pos-
pho-p27 single labelled cells could be made out by metic-
ulous scrutiny; in these tissues also MIB-1 staining was
sporadic.
pThr187-p27 expression in dysplastic and neoplastic 
tissues
As examples of dysplastic lesions, the expression of the
pThr187-p27 was assessed in low-and in high grade squa-
mous intraepithelial lesions (SIL) of the uterine cervix and
in colonic adenoma. According to the relationship
between phospho-p27 expression and proliferation, in
low grade SIL the dysplastic basal and parabasal cells were
in most instances positive for the expression of both
pThr187-p27 (Figure 2A), and Ki-67; these were instead
negative for "plain" p27 whose staining was confined to
the intermediate and superficial squamous cells, as
described [15]. In high grade SIL, the expression of phos-
pho-p27 correlated well with the extent of the dysplastic
cell population (Figure 2B), whereas "plain" p27 reactiv-
ity was restricted to very superficial layers displaying
squamous differentiation. In colonic adenoma pThr187-
p27 positive cells were randomly located throughout the
crypts and in contrast to that seen in normal mucosa, also
superficial cells were stained.
Table 2: Range of positive cells for pThr187-p27, "plain"-p27 and MIB-1 expression in different type of carcinomas
Histotype pThr187-p27 "plain" p27 MIB-1
ISCC cervix n = 9 45–60 5–30 50–78
ISCC oral n = 7 40–70 5–15 35–80
ISCC lung n = 10 15–60 5–70 30–70
Thyroid, papillary carcinoma n = 6 1–3 5–60 2–4
Thyroid, anaplastic carcinoma n = 5 23–45 5–11 41–55
Breast carcinoma n = 12 3–55 5–70 5–80
Colonic carcinoma n = 6 30–45 5–80 45–80
Prostate carcinoma n = 5 2.5–10 30–75 4–15
Glioblastoma n = 5 30–50 10–27 50–63
Chorioncarcinoma n = 2 45–55 3–7 60–80BMC Clinical Pathology 2005, 5:3 http://www.biomedcentral.com/1472-6890/5/3
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A wide range of different tumours was examined, in order
to assess whether staining for phospho-p27 may yield
diagnostic information in addition to those provided by
"plain p27" (Table 2). As a general rule, the expression of
the two forms of p27 was alternative and dependent on
the degree of tumour differentiation, recapitulating the
pattern featured by normal and dysplastic tissues; phos-
pho-p27 strongly labelled aggressive tumours, whereas
"plain p27" staining was only retained by well
differentiated tumours. Thus, poorly differentiated and
highly proliferating adenocarcinoma of the breast, colon
and prostate were strongly labelled by the pThr187-p27
Ab, (Figure 2C–D) whereas "plain p27" staining was only
retained by well differentiated neoplasms. The above
staining differences between the two forms of p27 were
also evident in squamous cell carcinomas. Poorly differ-
entiated neoplasms, composed of nests of small undiffer-
entiated cells with high MIB-1 index and minimal
keratinisation, showed intense staining for pThr187-p27
(Figure 2E) whereas "plain p27" labelled those neoplasms
showing abundant keratin, squamous pearl formation
and low mitotic activity. Similarly, anaplastic thyroid car-
cinoma showed pThr187-p27 staining stronger than pap-
illary carcinomas, while in this latter "plain p27" was
prevalent (Table 2). An intense pThr187-p27 expression
was also found in choriocarcinoma (Figure 2F), in which
p27 expression was detected by the pThr187 Ab p27 only in the proliferative compartments of normal tissues Figure 1
p27 expression was detected by the pThr187 Ab p27 only in the proliferative compartments of normal tissues. In tonsil (A) 
both parabasal squamous cells and lymphoid germinal cells were stained. In intestinal epitehlium only the nuclei of deep crypt 
cells were stained (B). Within the germinal centres, the outer rim of centroblasts and mitotic cells were strongly positive for 
pThr187-p27, whereas centrocytes were less labelled (C). Trophoblastic villi of placenta show pThr187-p27 intense staining 
only in the cytotrophoblastic layer and not in the syncytiotrophoblastic layer (D).
1A 1A 1B 1B
1C 1C 1D 1DBMC Clinical Pathology 2005, 5:3 http://www.biomedcentral.com/1472-6890/5/3
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the level of "plain-p27" staining was instead low. The
Spearman's correlation coefficient for continuous varia-
bles revealed a positive and a significant correlation
between pThr187-p27 staining and MIB-1 expression
(Spearman R = 0.88; p < 0,001). On the contrary both
pThr187-p27 and "plain" p27 (Spearman R = -0.61; p <
0,001) and MIB1 and "plain" p27 (Spearman R = -0.55; p
< 0,001) showed significant inverse correlations.
Immunostaining controls
Western blot analysis of MDA MB 468 (breast cancer) and
NPA (thyroid papillary cancer) cell lines revealed a single
anti-pThr187-p27 band, whose molecular weight (27
kDa) corresponded to that showed by "plain"-p27 (Fig.
3A). pThr187-p27 immunostaining specificity was con-
firmed by: (i) the disappearance of the signal when the
primary Ab was replaced by a similarly diluted normal
rabbit serum; (ii) the progressive signal quenching due to
the competitive inhibition between the increasing con-
centrations of the phosphopeptide and the phosho-p27
Ab. (Fig. 3 B–C).
Double IF & LSCM studies
Tissue sections from both normal and neoplastic speci-
mens were also stained using double IF labelling for
pThr187-p27 and "plain" p27 and analyzed by LSCM. The
use of an ultra sensitive detection system based on tira-
mide signal amplification for IF staining, revealed a more
precise pattern of protein expression and distribution,
slightly different to results above shown of regular colori-
metric IHC. In proliferative compartments of normal
tissues the cells frequently showed simultaneous expres-
sion of the two forms of p27; in these cells, pThr187-p27
was more localized as an inner rim along the nuclei mem-
brane, whereas "plain" p27 was more centrally located in
the same nuclei with an intermediate area of colocaliza-
tion (Fig. 4A). Similarly neoplastic nuclei also showed
simultaneous expression of the two p27 forms, frequently
The relationship between phospho-p27 expression and proliferation was evident both in low- (A) and high- (B) grade SIL, with  its expression correlating well with the extent of the dysplastic cell population Figure 2
The relationship between phospho-p27 expression and proliferation was evident both in low- (A) and high- (B) grade SIL, with 
its expression correlating well with the extent of the dysplastic cell population. Intense staining for phospho-p27 was also 
observed in the neoplastic cells of colonic (C) and lung (D) adenocarcinoma, in cervical squamous invasive carcinoma (E) and in 
choriocarcinoma (F)
2A 2A 2B 2B 2C 2C
2D 2D 2E 2E 2F 2FBMC Clinical Pathology 2005, 5:3 http://www.biomedcentral.com/1472-6890/5/3
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displaying high amounts of pThr187-p27 throughout the
whole nucleoplasm, colocalizing with "plain" p27. (fig-
ure 4B).
Discussion
p27 is an approved marker for quiescent cells, extensively
used in histopathology and cancer research. However here
we showed that an unusual p27 expression pattern may
be obtained when only its portion phosphorylated on
threonine 187 is stained. By using a specific
phosphorylation site antibody, p27 expression may be
detected in the proliferative compartments of squamous
and intestinal epithelia, of lymph node germinal centres,
of trophoblastic villi, of cervical and colonic pre-invasive
lesions and of several carcinomas types. These results are
similar to those reported in vitro by Montagnoli et al, who
also detected p27 expression in proliferating cells by the
pThr187-p27 Ab [6]. The same antibody, here, employed
to stain a wide range of normal, dysplastic and neoplastic
tissues yielded a pattern similar to that of Ki-67 (Spear-
man R = 0.88; p < 0,001), underlining the close associa-
tion between cell proliferation and the expression of that
portion of p27 targeted for degradation. Since pThr187-
p27 Ab should react with cells from late G1 through G2-
M, whereas MIB-1 stains throughout the entire cell cycle,
it is also conceivable that the pThr187-p27 Ab stained a
lower percentage of cells than MIB-1/Ki-67 in both nor-
mal (Table 1) and neoplastic tissue. (Table 2)
In this study we showed that p27 expression does not fea-
ture only one pattern, but that two different staining may
be obtained by the use of either regular or pThr187 anti-
bodies; in fact, when the overall data relative to the expres-
sion of p27 by both antibodies in tumours were analysed,
a significant inverse correlation between the two forms
was found (Spearman R = -0.61; p < 0,001). This data
reflects the different relationship between each form of
p27 and tissue differentiation:aggressive tumours were
strongly labelled by phospho-p27 Ab, whereas plain-p27
was prevalent in well differentiated tumours. Thus the
ratio between the two forms of p27, more than the total
Western blot analysis of MDA MB 468 (breast cancer) and NPA (thyroid papillary cancer) cell lines revealed a single anti- pThr187-p27 band, corresponding to that shown by the regular p27 antibodies Figure 3
Western blot analysis of MDA MB 468 (breast cancer) and NPA (thyroid papillary cancer) cell lines revealed a single anti-
pThr187-p27 band, corresponding to that shown by the regular p27 antibodies. (A). pThr187 staining of parabasal squamous 
cells (B) abolished by absorption of the antibody with the immunizing peptide.
3A 3A 3B 3B 3C 3CBMC Clinical Pathology 2005, 5:3 http://www.biomedcentral.com/1472-6890/5/3
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Coexpression of the forms of p27 in lymphoid germinal center (A) and in glioblastomas (B) Figure 4
Coexpression of the forms of p27 in lymphoid germinal center (A) and in glioblastomas (B). Simulataneous detection of p27 by 
both regular (green) and pThr187 (red) antibodies. Signal generated by the two antibodies Yellow areas (arrows) showed the 
colocalitation of the signal generated by both antibodies.
B B
A ABMC Clinical Pathology 2005, 5:3 http://www.biomedcentral.com/1472-6890/5/3
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protein amounts, could yield information on tumour dif-
ferentiation and behaviour.
Since cdk2 activity is low in differentiating cells and p27
is only present in its un-phosphorylated form, it is reason-
able that squamous superficial layers, upper half of the
intestinal crypts, lymphoid mantle cells and syncytiotro-
phoblastic cells only react with the regular antibodies.
More intriguing is the search for the reasons explaining
why in proliferating cells p27 is detected by the pThr187-
Ab and missed by the regular antibodies. The possibility
of an aberrant cross-reactivity by the pThr187-Ab was
excluded both by Western blot analysis and by
phosphopeptide adsorbtion. Montagnoli et al, who also
confirmed antibody specificity by biochemical assays,
showed that p27 expression may be better detected by
using both antibodies than either alone and that there is a
portion of p27 that is only recognizable by the anti-phos-
pho Ab [6]. Thus, in proliferating cells anti-pThr187 Ab
may be more efficient than the regular p27 antibodies,
being protein levels low and mainly present in their
phosphorylated form. To test this hypothesis, the sensitiv-
ity of the p27 detection by the regular antibodies was
increased by the use of an ultra sensitive detection system
based on tiramide signal amplification and observed at
high resolution by laser scanning confocal microscopy.
The results obtained by this approach were slightly differ-
ent to those obtained by colorimetric IHC, as p27 was
simultaneously detected by both antibodies in the same
nuclei of the proliferating compartments; in particular the
signal generated by both antibodies showed specific colo-
calitation by double immunofluorescence.
Conclusion
In this study we have reported the following observations:
(1) pThr187-p27 Ab selectively stains proliferating cells;
(2) this staining does not identify the "plain" p27 protein,
expressed by quiescent cells. Therefore, the pThr187-p27
antibody is a useful tool to study p27 in vivo regulation.
Indeed, the pattern of expression observed in this study,
strongly suggest that the anti-pThr187-p27 Ab identifies
proliferating cells. Considering the importance of the dif-
ferent biological functions of p27: regulator of cell
growth, cell differentiation, contact inhibition, apoptosis,
protection against immunological aggression, and
protection against environmental stress, among others,
the combined use of both "plain" and pThr187 p27 anti-
bodies will be a useful tool to better characterize the biol-
ogy of these conditions.
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